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HERPES ZOSTER RISK AND VACCINATION  
 
IN INFLAMMATORY BOWEL DISEASE PATIENTS 
 
 
DYLAN CLEMENS 
ABSTRACT 
 Patients with inflammatory bowel disease, particularly those on systemic 
immunosuppression, have been shown to be at increased risk of herpes zoster infection. 
Herpes zoster (also known as shingles) is a condition resulting from reactivation of 
varicella zoster virus (VZV), which causes chickenpox. VZV reactivation is thought to be 
due to impairment of cell-mediated immunity. Some immunosuppressive agents have 
been shown to be associated with higher risk for herpes zoster reactivation than others. 
Until recently, the only vaccine for herpes zoster was a live-attenuated vaccine, which is 
contraindicated in most immunosuppressed IBD patients due to their immunosuppressive 
therapy. Recently, an inactivated subunit vaccine has been developed and investigated for 
use in immunocompetent adults, as well as select groups of immunocompromised 
individuals. This novel vaccine has not yet been studied in IBD patients but holds 
promise for use in this population.  
The proposed study is a single-center prospective pilot study comparing 
immunogenicity and safety of the inactivated herpes zoster vaccine in patients with IBD 
(ulcerative colitis or Crohn’s disease) treated with high-level combination 
immunosuppression (both anti-TNF biologics and immunomodulators) to those not on 
systemic immunosuppressive therapy (5-aminosalicylates or no treatment). Investigators 
		 vi 
will compare cell-mediated responses between groups using an intracellular cytokine 
staining assay with flow cytometry assessed prior to vaccination and at four time points 
up to 12 months after completion of the immunization sequence. Adverse effects will also 
be monitored. This study will help to identify whether the novel herpes zoster vaccine is 
immunogenic and safe for use in IBD patients and whether these parameters are 
significantly impacted by intensity of immunosuppressive treatment. An additional goal 
is to provide preliminary data with which to develop future studies of vaccine 
immunogenicity and efficacy in this target population. 
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INTRODUCTION 
Background 
Inflammatory bowel disease (IBD), further classified as Crohn’s disease (CD) or 
ulcerative colitis (UC), is characterized by chronic gastrointestinal inflammation leading 
to various intestinal and extraintestinal manifestations, such as abdominal pain, diarrhea, 
and weight loss. IBD patients are typically treated with immunosuppressive drugs aimed 
at controlling the inflammatory process.1,2 These patients are already at increased risk of 
infection due to the disease itself; however, therapies that suppress the immune system 
further increase this risk.3  
One infectious condition seen more commonly in IBD patients than in the general 
population is herpes zoster (HZ).3 Also known as shingles, this condition results from 
reactivation of the varicella zoster virus (VZV) that causes chickenpox and typically 
presents with a distinct, painful rash. It is associated with a 1 in 3 lifetime risk in the U.S. 
among the general population;4 however, IBD patients are at increased risk of HZ 
infection due to the disease state and its treatments. It is believed that VZV reactivation 
occurs due to a decrease in cell-mediated immunity (CMI), which typically occurs with 
aging but is also seen among patients on immunosuppressive therapies.5 
 Therapeutic agents for IBD include 5-aminosalicylates, corticosteroids, 
immunomodulators, and biologics.1,2 Different degrees of risk for HZ have been 
attributed to different therapeutic regimens. In particular, conflicting data have been 
presented in the literature regarding the risk of HZ with anti-TNF biologics. The risk of 
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HZ associated with newer biologics used in IBD management, such as ustekinumab (anti-
IL-12/IL-23) and vedolizumab (anti-integrin), is still under investigation. 
A live-attenuated vaccine (Zostavax) is available and licensed by the FDA for 
individuals 50 years of age and older; however, it is still only recommended by the 
Advisory Committee on Immunization Practices (ACIP) for use in patients 60 years or 
older.5,6 It has an efficacy of 51.3% with regard to preventing HZ and has also been 
shown to reduce the risk of post-herpetic neuralgia (PHN), a complication of HZ.7 Many 
patients with immune deficiencies are not eligible for HZ vaccination due to it being a 
live vaccine. IBD patients on low-dose immunomodulators are not prohibited from 
receiving the vaccine; however, anti-TNF therapy is presently a contraindication.6  
 
Statement of the Problem 
Although the live-attenuated vaccine for HZ is recommended for IBD patients, many are 
unable to receive it due to their medical treatment. Additionally, several studies suggest 
that HZ vaccination rates among IBD patients are low, potentially due to a lack of 
awareness of vaccination guidelines or concerns about administering live vaccines to IBD 
patients.8,9 Thus, the current vaccination approach for HZ is likely suboptimal and 
alternative strategies for prevention are needed. 
 A novel inactivated herpes zoster subunit vaccine (HZ/su) was licensed by the 
FDA in October 2017.10 Initial studies demonstrated efficacy rates greater than 90% in 
immunocompetent patients,11,12 and two studies in immunocompromised populations 
(HIV-positive patients, hematopoietic cell transplant recipients) have suggested favorable 
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immunogenicity and safety profiles.13,14 This holds promise for use in IBD patients on 
immunosuppression; however, no studies in IBD patients have been performed.15 Further 
research is needed to evaluate the use of this vaccine in the IBD population. If it is 
demonstrated that HZ/su is protective and safe in these patients, this offers an alternative 
strategy for reducing the morbidity and mortality associated with HZ in this at-risk group. 
 
Hypothesis 
Based on existing studies demonstrating the immunogenicity and safety of HZ/su in 
patients with CMI deficiencies, patients with IBD treated with biologic agents and 
immunomodulators will be able to mount a significant but lesser cell-mediated immune 
response to the vaccine compared to IBD patients not on systemic immunosuppression. 
 
Objectives and specific aims 
The proposed study will focus on demonstrating the immunogenicity and safety of the 
HZ/su vaccine in IBD patients treated with combination therapy with anti-TNF agents 
and immunomodulators (AZA, 6-MP, MTX) compared to IBD patients not on systemic 
immunosuppression (5-ASA or no therapy). Specific aims of this study will be: 
• To assess the immunogenicity of HZ/su in the study population via a measure of 
cell-mediated immunity: intracellular cytokine staining and flow cytometry 
• To evaluate the safety of HZ/su in the study population via identification of local 
and systemic reactions to the vaccine and any serious adverse events or cases of 
herpes zoster during the trial period 
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• To provide preliminary data regarding expected CMI measurements in IBD 
patients with which to inform the development of future, larger studies 
	5 
REVIEW OF THE LITERATURE 
Overview 
Inflammatory bowel disease is characterized by chronic gastrointestinal inflammation 
with clinical features such as abdominal pain and diarrhea and additional intestinal and 
extraintestinal complications, including bowel strictures, fistulae, malabsorptive 
conditions, skin lesions, and arthropathy. There are specific endoscopic and 
histopathologic features that aid in making the diagnosis.1 The two major subtypes are 
ulcerative colitis and Crohn’s disease. It is estimated that UC affects 37 to 246 of every 
100,000 persons and that CD affects 26 to 199 of every 100,000 persons in North 
America. About 7,000 to 46,000 people are newly diagnosed with UC and 10,000 to 
47,000 are newly diagnosed with CD each year. The incidence has also been found to be 
increasing.16,17 In addition to the above clinical features, patients with IBD are at 
increased risk of infectious complications due to the disease itself and to 
immunosuppressive agents used in its management.3  
One such infectious condition is herpes zoster (otherwise known as shingles), the 
condition resulting from reactivation of the varicella zoster virus that causes chickenpox 
in its primary form.5 Herpes zoster is characterized by a unilateral, painful, vesicular rash 
along the dermatomal distribution of 1-2 sensory nerves. This distinctive presentation 
results from the propagation of the virus along the nerve in which it has remained 
dormant since the resolution of the primary varicella infection. Onset of pain may 
precede the rash by several days and may be severe. This disease is typically self-limiting 
and resolves within a few weeks but may lead to significant complications, including 
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post-herpetic neuralgia (PHN), a chronic pain syndrome lasting for weeks to years; zoster 
ophthalmicus, which may lead to blindness; zoster oticus (Ramsay-Hunt Syndrome), 
which may result in deafness; disseminated zoster; and zoster meningitis.5 These 
complications can cause significant morbidity and mortality, and, therefore, prevention of 
HZ is an important consideration in management of IBD patients.  
Epidemiology of herpes zoster 
 Herpes zoster has an estimated incidence of 3-5 cases per 1,000 person-years, 
accounting for approximately 1 million incident cases per year in the U.S.4,18 It is 
associated with a 1 in 3 lifetime risk in the United States and is typically seen in older 
individuals.4 IBD patients have been found to be at an increased risk of HZ infection—
twice the risk seen in the general population according to some studies.3,19,20 Additional 
risk factors for zoster include increasing age and immunocompromised state, be that 
related to an immune-mediated disorder or medical therapy.18 Specifically, advancing age 
is associated with waning cell-mediated immunity (CMI), a process known as immune 
senescence, which predisposes patients to developing HZ.5 
Pathophysiology of herpes zoster infection and host immune response 
 The pathophysiology of HZ reactivation is not well understood. It is believed that 
after initial infection with VZV, the virus remains dormant in the dorsal root ganglion of 
a sensory nerve until some compromise of the host’s cell-mediated immunity allows the 
virus to replicate and propagate down the nerve.5,21 Either the wild-type strain or the Oka 
vaccine strain can reactivate to cause herpes zoster.5 
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 CMI is believed to play the predominant role in preventing VZV reactivation. It 
has been observed that patients with defects in CMI (e.g. HIV infection, organ transplant) 
are at increased risk of HZ infection compared to healthy controls, while patients with 
defects in humoral immunity are not similarly affected.21 An immunology substudy of the 
Shingles Prevention Study, which analyzed the efficacy, immunogenicity, and safety of 
the Zostavax vaccine, sought to further characterize the immune response to HZ 
vaccination.22 This study noted that CMI responses decreased with age—consistent with 
the age-related increase in HZ incidence—while decreasing antibody responses were not 
significantly associated with advancing age. While the vaccine was found to boost CMI 
measures and antibody levels, no specific correlation between CMI and humoral 
measures was found, suggesting that these function independently in the HZ immune 
response.22 An additional study by Weinberg et al23 sought to correlate the immune 
response to HZ with illness severity and found that patients reporting lower severity 
scores had higher measures of CMI early in the course of infection, while antibody levels 
showed no correlation early in the infection. Antibody levels were higher in patients with 
more severe disease when measured three weeks after onset of rash, but this was thought 
to be reactionary in response to increased antigenic stimulation.23  
 Some studies have sought to evaluate the utility of antibody levels as a correlate 
of protection against HZ in vaccinated patients. An immunology substudy of one of the 
large trials investigating the live-attenuated zoster vaccine, Zostavax, measured anti-VZV 
antibody levels 6 weeks post-vaccination and correlated these responses with risk of 
developing HZ.24 Vaccine recipients had a statistically significantly higher geometric 
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mean titer (GMT) compared to placebo and a geometric mean fold rise (GMFR) from 
baseline of 2.31, compared to a GMFR of 1.0 in the placebo group. Six-week antibody 
responses were significantly inversely correlated with HZ risk, but no specific protective 
threshold level was determined. Of note, those who received placebo and did not develop 
HZ still had a lower GMT than vaccine recipients who did, suggesting the higher 
antibody levels were not sufficient to protect against VZV reactivation. It was concluded 
that antibody responses are likely not directly protective against HZ but may provide a 
non-mechanistic means of assessing vaccine response; they may be predictive of an 
adequate immune response despite not being responsible for the protection.24 This study 
only looked at healthy individuals, however, and did not assess CMI. As CMI and 
humoral immunity are thought to function independently in the response to VZV 
infection, this may not be as useful a measure alone in patients with immune deficits 
affecting one arm of the immune system more than the other. The immune response to 
HZ and appropriate measures of that response are important concepts to consider when 
evaluating vaccine responses. 
Vaccination for herpes zoster in IBD patients 
 A live-attenuated vaccine, known as Zostavax, was developed by Merck & Co. 
and licensed in 2006 by the FDA. This vaccine utilizes the Oka strain of the varicella 
zoster virus, the same as that used in vaccination for primary varicella but at much higher 
potency. It was initially approved only for patients 60 years of age and older; however, it 
was later approved for use in 50-59 year olds, as well.5,6 Despite this change in approval 
by the FDA, the Advisory Committee on Immunization Practices (ACIP) has maintained 
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its recommendation for use only in patients 60 or older.5,6 The Shingles Prevention Study, 
a large, randomized, double-blind, placebo-controlled clinical trial performed to evaluate 
the efficacy and safety of the vaccine in patients 60 years of age and older demonstrated 
an efficacy of 51.3% for prevention of HZ and a 66.5% reduction in cases of PHN.7 
 Based on current American College of Gastroenterology (ACG) guidelines, 
vaccination against HZ may be considered for IBD patients aged 50 and above.6 A large 
retrospective cohort study by Zhang et al25 demonstrated no significant difference in the 
incidence rate of zoster in vaccinated compared to unvaccinated patients with 
autoimmune and inflammatory conditions, including IBD. However, despite the large 
study sample, only a small proportion of patients actually received the vaccine and few 
cases of HZ were identified. This makes it difficult to draw efficacy conclusions from 
this study; however, the lack of a short-term increase in HZ incidence suggested that this 
vaccine was safe in non-immunosuppressed IBD patients. An additional large 
retrospective cohort study by Zhang et al26 found an adjusted hazard ratio of 0.61 (95% 
CI 0.52-0.71) with respect to incidence of HZ in vaccinated patients with inflammatory 
diseases, including IBD. Both of these studies had limitations with respect to their study 
sample, as both utilized administrative medical claims data rather than direct patient 
medical records, were unable to account for disease severity, and did not provide efficacy 
data specifically for IBD patients. However, they did suggest that patients with immune-
mediated diseases would tolerate the vaccine and likely gain some protective benefit.  
 Despite the availability of a vaccine for HZ prevention, many IBD patients are 
unable to receive it, as they are treated with immunosuppressive medications, which in 
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many cases represents a contraindication to receipt of live vaccines.5 In these patients, it 
is recommended that vaccination with live vaccines such as Zostavax be given prior to 
initiation of high-dose immunosuppressive therapy.5 Current guidelines do state that 
patients treated with low doses of methotrexate, azathioprine, or 6-mercaptopurine5 may 
receive the vaccine, as this low degree of immunosuppression is considered unlikely to 
carry significant risk of contracting the infection with live vaccines. A small prospective 
study by Wasan et al27 investigated the immunogenicity and safety of Zostavax in 
patients on low-dose immunosuppression compared to those not treated with systemic 
immunosuppression. This study demonstrated that these patients were able to mount a 
statistically significant humoral and CMI response to the vaccine, although the response 
was slightly reduced compared to their less immunosuppressed counterparts. No adverse 
events were detected in this study in response to the vaccine. Vaccination in patients 
currently treated with higher level immunosuppressive regimens, including biologics 
such as anti-TNF therapies, is controversial and generally not recommended.5,6 
Vaccination issues in IBD patients  
Despite current recommendations and the infectious risks associated with IBD, 
many patients do not receive all appropriate vaccinations. A large retrospective cohort 
study assessing the use of the HZ vaccine based on administrative claims data from 2005 
to 2009 found that only 1.25% patients with various autoimmune diseases received the 
vaccine and, for IBD specifically, only 1.6% of patients in this study were vaccinated. 
This study is limited in that it assessed vaccination status based on claims data during a 
time period in which the vaccine was still fairly new.25 A more recent study by Wasan et 
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al9 based on an online survey of IBD patients in 2012 showed a self-reported HZ 
vaccination rate of 33.3%. This study relied on voluntary participation and self-reports of 
IBD diagnosis and immunization status and, thus, was subject to selection and recall 
biases. However, these studies illustrate the suboptimal rates of vaccination for this 
potentially preventable disease.  
Some potential contributing factors to the low vaccination rates in IBD patients 
may be poor understanding of the vaccination guidelines by gastroenterologists, 
disagreement regarding who is responsible for providing vaccines, and concern about 
administering live vaccines to immunosuppressed persons.8 In a study by Wasan et al,8 
108 gastroenterologist members of the ACG were surveyed regarding knowledge of 
current vaccination guidelines in IBD patients. Only 12% of respondents were able to 
identify all appropriate vaccines for IBD patients correctly, while 20-30% reported that 
they would give live-attenuated vaccines to immunosuppressed patients and 24-35% 
reported that they would not give these to immunocompetent patients. The majority of 
those sampled felt that it was the responsibility of the primary care provider to determine 
the vaccination schedule and administer the appropriate vaccines. 
Immunosuppressive therapy in IBD 
 The primary forms of therapy for IBD function by suppressing the chronic 
inflammatory response, and, while immunosuppression has proven to be effective in 
treating IBD patients, it also predisposes them to opportunistic infections, such as HZ.1,2 
Current therapeutics utilized in IBD management include 5-ASA products (e.g. 
mesalamine), corticosteroids, immunomodulators (e.g. thiopurines, methotrexate), and 
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biologic agents (anti-TNF-α agents, integrin inhibitors, interleukin inhibitors). JAK 
kinase inhibitors, such as tofacitinib, are under investigation for use in IBD patients as 
well.1,2 5-ASA products are anti-inflammatory medications considered to act only 
topically and not to induce systemic immunosuppression.27 Therefore, the following 
sections will discuss the risk of HZ associated with steroids, immunomodulators, and 
biologic therapies, with particular focus on the latter group. 
Corticosteroids and herpes zoster risk 
 With regard to treatment for IBD, corticosteroids are commonly used in the 
setting of acute flares and act by altering gene expression and inhibiting various pro-
inflammatory pathways, including NF-κβ and arachidonic acid derivative pathways.1,2  
 Steroid use has been found in several studies to be associated with an increased 
risk of HZ, generally in a dose-dependent manner. One meta-analysis by Marra et al28 
found that all but two of fifteen observational studies in patients with autoimmune 
diseases (including IBD, RA, psoriasis, psoriatic arthritis, and lupus) reported a 
statistically significant increased risk of HZ with increasing steroid dose with an overall 
adjusted odds ratio of 1.73 (95% CI 1.57-1.89). Several large retrospective cohort studies 
have shown similar results in patients with various immune-mediated diseases, reporting 
adjusted odds ratios or hazard ratios between 1.5 and 3.0.3,20,26,29 Yun et al29 noted an 
adjusted HR of 1.55 (95% CI 1.25-1.93) for HZ in patients on ≤7.5 mg/day of prednisone 
and 2.35 (95% CI 1.81-3.04) for patients on >7.5 mg/day compared to no corticosteroids. 
A major limitation of many of these studies is their use of medical claims data, which 
relies on prescription information and makes it difficult to accurately quantify patients’ 
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actual steroid use. However, this association has been found in multiple different studies, 
and, therefore, steroid use is often accounted for as a potential confounder in analyses of 
HZ risk with other agents. 
Immunomodulators and herpes zoster risk 
 Immunomodulators include thiopurines (azathioprine [AZA] and 6-
mercaptopurine [6-MP]) and methotrexate (MTX). They are utilized as both induction 
and maintenance therapy for IBD, alone or in combination with other drugs. Thiopurines 
function as antimetabolites and inhibit purine synthesis, thereby impairing nucleic acid 
synthesis and cell proliferation; they also limit inflammation by inducing apoptosis of T 
lymphocytes.1,2 Methotrexate is a dihydrofolate reductase inhibitor, impairing synthesis 
of thymidine and, ultimately, nucleic acid synthesis and cell proliferation. Additionally, it 
impairs synthesis of cytokines and other pro-inflammatory molecules, accounting for its 
anti-inflammatory function.1,2 
 Several studies have attempted to characterize the contribution of 
immunomodulators to HZ risk with mixed findings. A meta-analysis by Marra et al28 did 
not find a significant increase in risk of HZ associated with MTX compared to control 
(pooled OR 0.89, 95% CI 0.24-3.29, P=0.834) based on five RCTs. Additionally, several 
retrospective cohort studies in RA patients have also found no statistically significant 
increase in HZ risk associated with MTX use.29,30 A nested case control study assessing 
185 patients with CD and 266 patients with UC with HZ, matched with 1787 IBD 
patients without zoster, demonstrated an increased risk of HZ (adjusted OR 3.1, 95% CI 
1.7-5.6) associated with use of AZA or 6-MP within 30 days prior to rash onset, although 
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no significant increase in risk was associated with use of these agents >30 days prior to 
rash onset.3 Another nested case control study demonstrated an increased risk of HZ 
associated with thiopurine use (OR 1.85, 95% CI 1.61-2.13).20 Many of these studies are 
retrospective administrative data based studies and are unable to quantify 
immunomodulator dosing, which is a major limitation to determining risk. Despite this, 
immunomodulator therapy is considered to be a risk factor for HZ in IBD patients.6 
Biologic agents and herpes zoster risk 
 Biologics are targeted therapeutic agents utilized in IBD management and include 
anti-TNF-α agents (e.g. infliximab, adalimumab, certolizumab, golimumab), the anti-IL-
12/IL-23 monoclonal antibody ustekinumab, and the newer anti-integrin monoclonal 
antibody vedolizumab. There is presently a fair degree of controversy regarding the 
respective associations between biologic use and HZ risk, as well as the implications for 
vaccination in patients undergoing biologic therapy. 
  Anti-TNF agents have become important therapeutics for IBD management, both 
as monotherapy and in combination with other medications. TNF-α is a cytokine that 
mediates multiple inflammatory pathways in IBD, making it a powerful target for anti-
inflammatory therapy.2 Despite several published studies evaluating the risk of HZ in 
anti-TNF-treated patients, there is not currently a consensus on this matter. Given the 
relative rarity of HZ events, the majority of the current literature relies on retrospective 
data from large databases. A nested case control study by Long et al20 evaluated 
treatment-specific HZ risk in IBD patients 18-65 years of age and found an adjusted OR 
of 1.81 (95% CI 1.48-2.21) associated with anti-TNF therapy (including infliximab, 
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adalimumab, and certolizumab). Of note, a further increase in risk was found with 
combination therapy involving an anti-TNF agent and thiopurine compared to 
monotherapy with either class (adjusted OR 3.29, 95% CI 2.33-4.65). A prospective 
cohort study utilizing a German biologics registry in RA patients identified a statistically 
significant increase in HZ incidence (adjusted HR 1.82, 95% CI 1.05-3.15) associated 
with use of infliximab or adalimumab, although this result did not meet the prespecified 
criterion for clinical significance set by the researchers.30 Marehbian et al31 noted a rate 
ratio of 2.90 (95% CI 1.72-4.89) for HZ infection associated with anti-TNF use in CD 
patients compared to the general population. However, when anti-TNF therapy was 
compared to no therapy within the CD cohort, the association was not statistically 
significant (adjusted HR 1.33, 95% CI 0.42-4.25). Other studies in patients with immune-
mediated diseases have shown no significant risk of HZ with anti-TNF therapy, including 
a meta-analysis by Marra et al28 analyzing over 20 randomized controlled trials. This 
meta-analysis did suggest an increased risk of HZ with biologics as a broad class based 
on observational study data, but, when stratified based on anti-TNF and non-anti-TNF 
agents, there was a higher risk of HZ with non-anti-TNF biologics and no statistical 
difference found for anti-TNF agents alone. A retrospective cohort study by Winthrop et 
al32 found no significant increase in HZ risk with infliximab or adalimumab compared to 
thiopurines in over 10,000 IBD patients. An additional large retrospective cohort study in 
psoriatic patients did not identify a significant association between HZ and infliximab or 
adalimumab compared to treatment-free control periods.33 In this study, the control 
periods were defined as any time at least 6 months following cessation of treatment in 
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those previously treated with the studied drugs or any period of time in patients not 
treated with them. HZ cases were attributed to treatment if they occurred during treatment 
periods or within 6 months of cessation. One large retrospective cohort study in RA 
patients sought to characterize any differential risk of HZ among specific anti-TNF 
agents (adalimumab, certolizumab, golimumab, infliximab), and, while crude incidence 
rates for certolizumab and golimumab were found to be highest and lowest among the 
class, respectively, no statistically significant differences were found among any agents 
after adjustment for potential confounders.29 Ultimately, HZ risk among anti-TNF users 
is controversial at this time, making it difficult to provide recommendations on 
vaccination guidelines for IBD patients on these regimens. 
 Ustekinumab is a monoclonal antibody that acts as an antagonist of IL-12 and IL-
23, cytokines implicated in inducing T-cell responses as part of the inflammatory 
pathophysiology of Crohn’s disease.2 Few studies have specifically assessed the 
association between ustekinumab and HZ risk, and most studies that include ustekinumab 
in their analysis have been performed in psoriasis patients. One large retrospective cohort 
study utilizing records from an Israeli national health services database to evaluate HZ 
risk among 95,941 patients with psoriasis, contributing 522,616 person-years, found an 
adjusted rate ratio of 2.67 associated with ustekinumab use; however, this was not 
statistically significant (95% CI 0.69-10.30, p=0.14).33 Notably, only 63 patients of the 
entire cohort were treated with ustekinumab, limiting the study’s ability to detect a 
significant difference despite the very large sample in the overall study. A systematic 
review by Adelzadeh et al34 evaluating the risk of HZ associated with biologic use in 
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patients with psoriasis and other immune-mediated diseases identified only one 
retrospective cohort study in which use of ustekinumab was analyzed. This study was 
similarly limited by a small sample size and found a non-significant increase in incidence 
rate of HZ with ustekinumab use.34 Two case reports of HZ were also identified in 
patients treated with ustekinumab for plaque psoriasis.34 In light of the very limited data 
available, the risk of HZ with ustekinumab is incompletely characterized at this time. 
 Vedolizumab is a monoclonal antibody directed against the α4β7 integrin, a T-cell 
ligand of the MAdCAM-1 adhesion factor. MAdCAM-1 is expressed primarily in the 
vasculature of gastrointestinal mucosa, and, therefore, vedolizumab is thought to inhibit T 
cell trafficking in a gut-specific manner.2,35 As vedolizumab is a newer agent, there are 
few studies assessing its impact on HZ risk. One study aggregated safety data from six 
phase 2 to 3 trials to assess the risk of various infectious conditions with vedolizumab 
and found a lower rate of infectious events associated with vedolizumab compared to 
placebo.36 This study did not specifically evaluate for HZ risk but included abdominal, 
respiratory, skin and soft tissue, and urinary tract infections as well as other types. Most 
infections seen with vedolizumab use were respiratory infections; no cases of 
disseminated HZ were reported. A meta-analysis by Shah et al37 did not identify an 
overall increased risk of infection in vedolizumab-treated patients based on two 
randomized controlled trials (CD: pooled relative risk 1.10, 95% CI 0.97-1.25; UC: 
pooled relative risk 1.02, 95% CI 0.88-1.16). A study designed to further characterize the 
gut-selectivity of vedolizumab by evaluating the response of patients to vaccines 
administered enterally (oral cholera vaccine [OCV]) versus parenterally (hepatitis B 
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vaccine [HBV]) demonstrated a statistically significant reduction in OCV response 
compared to HBV, suggesting that the immunosuppressive activity of vedolizumab is 
mediated primarily in the GI tract rather than systemically.35 Although there are few 
studies specifically addressing HZ risk with this drug, it is plausible that patients treated 
with vedolizumab are not at significantly increased risk for HZ given its specific site of 
action; however, further studies are needed to characterize the treatment-associated risk.  
JAK kinase inhibitors and herpes zoster risk 
While it is not yet utilized for IBD, tofacitinib is a JAK kinase inhibitor under 
investigation for use in these patients and has been associated with a significantly 
increased risk of HZ compared to placebo and biologic therapy in studies of rheumatoid 
arthritis patients.38,39 Initial studies in UC patients have suggested higher rates of HZ in 
this group as well.40 Its contribution to risk of HZ should be further investigated in IBD 
patients if it is to be used in this population. 
Immunosuppression and response to vaccination 
 It is also important to consider whether patients who are immunosuppressed are 
able to mount protective immune responses to vaccines. There is some evidence from 
prospective trials to suggest that IBD patients treated with anti-TNF monotherapy or 
combination therapy with an immunomodulator have an impaired response to the 
pneumococcal vaccine, while those treated with thiopurine monotherapy do not have a 
significantly reduced response.41 A meta-analysis of nine prospective studies in 1,474 
IBD patients reported an overall reduction in vaccine response rate to hepatitis A, 
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hepatitis B, pneumococcal, and/or influenza vaccines of approximately 60% in patients 
treated with immunosuppressive medications.42 More specific analyses revealed a 
reduction in vaccine response rate of 70% with anti-TNF agents (infliximab, 
adalimumab, certolizumab), 40% with immunomodulators (MTX, 6-MP, AZA), and 65% 
with combination therapy with steroids, immunomodulators, and/or anti-TNF drugs. Of 
note, these studies only evaluated humoral responses to vaccines and, thus, may not be 
directly applicable to vaccines relying on CMI protection. 
 Wasan et al27 did evaluate the immune response to HZ vaccination among patients 
on low-dose immunosuppression and demonstrated a statistically significant humoral and 
cell-mediated immune response to the vaccine, although this response was reduced in 
comparison with IBD patients not treated with systemic immunosuppressive agents. A 
statistically significant response, however, does not necessarily correlate with clinical 
protection, and, therefore, the clinical efficacy of vaccination in this population cannot be 
inferred from these findings. Anti-TNF therapy is currently a contraindication for 
Zostavax. However, interestingly, in a large retrospective cohort study, patients with 
various immune-mediated diseases on anti-TNF therapy who did receive the HZ vaccine 
during therapy did not develop HZ within 6 weeks following vaccination and had a lower 
incidence rate of HZ than those on anti-TNF therapy who were not vaccinated.26  
 
Existing research 
Given the increased incidence of HZ in IBD patients and the limited vaccination options 
in these patients, alternative zoster vaccination strategies are needed. Fortunately, a new 
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inactivated subunit vaccine has been developed and is under investigation for use in both 
immunocompetent and immunocompromised patients. The herpes zoster subunit vaccine 
(HZ/su, trade name “Shingrix”) was developed by GlaxoSmithKline and was licensed by 
the FDA in October 2017 for patients 50 years of age and older.10 The vaccine itself is 
composed of VZV glycoprotein E (gE), a target of the immune response against the virus 
and a component implicated in viral replication, as well as an adjuvant system (AS01B) 
included to bolster the immune response against the viral antigen.12,43 As the vaccine is 
still very new, published research is limited. Therefore, this analysis will focus on those 
few important studies available. No published studies have focused on IBD patients; only 
trials in other immunocompromised patients have been completed.   
Efficacy, immunogenicity, and safety of HZ/su in immunocompetent patients 
 Initial studies in immunocompetent individuals demonstrated a high degree of 
immunogenicity in these patients, although with a higher rate of adverse reactions 
compared to placebo. The first phase 1/2 randomized open-label clinical trial to evaluate 
this new vaccine focused on comparing HZ/su with the Oka vaccine (Zostavax).44 
Patients in the older cohort of this study (age 50-70) were randomized equally into three 
groups: HZ/su alone, Oka alone, HZ/su plus Oka. Immunogenicity measures were 
assessed with blood samples taken before vaccination and at various selected time points 
during the study. CMI measures included intracellular staining (ICS) for markers of T 
cell activation (IFN-γ, TNF-α, IL-2, CD20 ligand) after stimulation with VZV antigens; 
positively responding cells were defined by expression of at least two markers. Humoral 
immunity was assessed by anti-VZV and anti-gE antibody titers measured by ELISA 
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assays. There was a statistically significant increase in CMI parameters in the HZ/su 
groups compared to Oka alone and no significant difference found between the two 
HZ/su groups. Greater humoral immune response rates were noted for HZ/su-containing 
regimens than Oka alone. More generalized and local reactions were noted in the HZ/su-
containing groups than with Oka alone; however, no vaccination-related serious adverse 
events, significant laboratory abnormalities, or confirmed cases of HZ were reported. A 
follow-up study to evaluate the persistence of the immune response at 12, 30, and 42 
months after the first dose demonstrated a decline in frequency of positively responding 
CD4+ T cells, but CMI measures remained higher than at baseline. This study 
demonstrated that HZ/su was more immunogenic than Zostavax with an acceptable safety 
profile, although with slightly more adverse effects than the live-attenuated vaccine and 
no established relationship between immunogenicity and clinical efficacy. As mentioned 
previously, CMI is considered to be crucial to preventing VZV reactivation, and the 
inclusion of both CMI and antibody assays strengthens its validity.  
 The high degree of immunogenicity and higher rate of side effects has been 
attributed to the AS01B adjuvant system used in the vaccine. A phase 2 single-blind 
randomized controlled study in over 700 patients evaluated CMI and humoral immune 
responses to different vaccine formulations: a two-dose regimen of unadjuvanted gE; 
three two-dose regimens of adjuvanted gE with different doses (25, 50, and 100 µg); and 
a one-dose regimen of a 100 µg adjuvanted gE vaccine.43 This study demonstrated 
enhanced CMI and humoral responses to the two-dose adjuvanted formulations compared 
to the unadjuvanted and single-dose adjuvanted formulations. The two-dose adjuvanted 
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groups also demonstrated more persistent responses over time. Antigen dose had no 
significant effect on CMI response, but the 25 µg gE adjuvanted group demonstrated a 
poorer humoral response than the 50 µg or 100 µg groups, between which there was no 
significant difference. The adjuvanted groups all demonstrated a greater rate of solicited 
local and systemic reactions compared to the unadjuvanted group. Based on this study, it 
was determined that the AS01B adjuvant system is likely responsible for enhancing the 
immune response to the gE antigen and has also been implicated in the higher rate of 
adverse reactions seen with HZ/su compared to Zostavax. 
 A long-term persistence follow-up study was performed in 129 patients who 
received two doses of the 50 µg gE/AS01B vaccine.45 This demonstrated a reduction in 
gE-specific CD4+ T cell frequency of 25% between year 3 and 6 after the first dose, but a 
mean 3.8-fold increase over pre-vaccination CMI measures was seen at the 6 year point. 
Antibody levels also decreased by 20% between year 3 and year 6 but remained higher 
than pre-vaccination levels by 7.3-fold at the 6 year mark. Immune responses were 
similar in 60-69 and 70+ year age groups. No serious adverse events related to the 
vaccine were identified, and only one self-limited potential HZ case was seen. This study 
was limited in that it had no control comparisons and that immune parameters could not 
be correlated directly to vaccine efficacy, but the maintenance of statistically significant 
CMI and humoral immune responses 6 years from vaccination was encouraging. 
While initial studies focused on safety and immunogenicity, they were unable to 
correlate immune response with protection against HZ, as incidence rates were not 
assessed and no threshold immune response has been established for HZ protection. A 
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phase 3 randomized, double-blind, placebo-controlled study (ZOE-50) was carried out in 
a cohort of 15,411 subjects 50 years of age and older with the primary endpoint being 
vaccine efficacy in terms of HZ risk reduction.12 Secondary endpoints included safety, 
reactogenicity, and efficacy by age group. Participants were randomized to receive two 
doses of HZ/su or placebo two months apart. Suspected cases of HZ were confirmed by 
PCR analysis of vesicular fluid for VZV DNA or by unanimous agreement of a 
committee if PCR results were negative. This study revealed a vaccine efficacy of 97.2% 
(95% CI 93.7-99.0, p<0.001) in the entire study population with no significant difference 
in vaccine efficacy found between age groups. Subjects receiving the HZ/su vaccine did 
exhibit higher rates of local and systemic reactions (84.4% in vaccine group, 37.8% in 
placebo group); however, serious adverse events were rare and seen at similar rates in 
both groups (1.1% in vaccine group, 1.3% in placebo group) with only four considered 
directly related to the study interventions. Ultimately, this study demonstrated a high 
vaccine efficacy rate in patients 50 years of age and older. Additionally, efficacy was 
found to be similar across age groups, whereas Zostavax demonstrated decreased efficacy 
with advancing age.7 
 The above study, ZOE-50, demonstrated the efficacy of HZ/su in preventing HZ 
infection but did not assess its effect on disease severity or prevention of complications in 
those who did develop the infection after receipt of the vaccine. An additional 
randomized, placebo-controlled phase 3 trial was carried out in 14,816 patients 70 years 
of age and older (ZOE-70) and took place concurrently with ZOE-50. This study intended 
to focus on vaccine efficacy in preventing HZ in elderly subjects but also assessed for 
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PHN prevention in the combined cohort of ZOE-50 and ZOE-70. Study methods were the 
same as those for ZOE-50. Overall vaccine efficacy was found to be 89.8% (95% CI 
84.2-93.7, p<0.001) for the ZOE-70 cohort with no significant difference found between 
participants 70-79 and 80+ years old. Researchers also performed a pooled analysis of 
patients from ZOE-70 and patients in the 70+ age group from ZOE-50 and found a 
vaccine efficacy of 91.3% (95% CI 86.8-94.5). HZ/su was found to be 88.8% effective 
(95% CI 68.7-97.1) in preventing PHN among patients with HZ in the pooled 70+ cohort 
and 91.2% effective (95% CI 75.9-97.7) in patients 50 years of age and older with HZ 
from both studies. This study added further evidence that the HZ/su vaccine was effective 
in preventing HZ and, additionally, demonstrated efficacy in preventing PHN among 
older adults who did develop HZ. 
 An additional consideration with respect to HZ vaccine utility is its effectiveness 
in patients who have already developed HZ infection in the past, as HZ infection itself 
does not confer complete protection against recurrences,46 and none of the previous 
studies included patients with a prior history of HZ. One small multicenter phase 3 trial 
assessed the immunogenicity and safety of this vaccine in patients with a prior history of 
HZ.46 This was a non-randomized, open-label study in 96 unvaccinated patients 50 years 
of age and older with a history of HZ. Immunogenicity was assessed by anti-gE antibody 
levels (prior to vaccination and one month after the second dose of vaccine), and a four-
fold increase in antibody concentration over baseline was considered a positive vaccine 
response. According to this criterion, the vaccine response rate was 90.2% (95% CI 81.7-
95.7), and antibody levels were similar regardless of age. As in prior studies, there was a 
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high rate of solicited adverse reactions (77.9% reporting local reactions, 71.6% reporting 
generalized reactions). Nine cases of HZ in 6 patients were reported, although none were 
confirmed by laboratory assessment and three of these patients did not receive the second 
dose of the vaccine. This study suggested that the HZ/su vaccine is immunogenic in 
patients with a prior history of HZ; however, no measures of CMI were evaluated, and, as 
has been described, CMI is believed to be the predominant immunologic mechanism in 
prevention of VZV reactivation. It is unclear if the boosted humoral immunity correlates 
with protection against disease, and, thus, efficacy conclusions cannot be drawn from 
these results. GMTs did appear to be similar in magnitude or greater than those seen in 
the study performed by Leroux-Roehls et al,44 although no direct correlation between 
CMI and humoral immunity was described in that study. This study also lacked control 
subjects for comparison, cases of HZ were self-reported in some instances, and no 
confirmation of HZ cases was required. Despite these limitations, this study did display a 
similar safety profile in patients with prior HZ infection to that seen in patients without 
prior HZ in other studies.  
 In summary, based on several clinical trials, HZ/su has been demonstrated to be 
efficacious in preventing HZ in older individuals, immunogenic with respect to CMI and 
humoral immunity parameters, and safe in immunocompetent individuals, although with 
a higher rate of mild to moderate transient adverse reactions compared to the live-
attenuated HZ vaccination. This vaccine may even be more effective than the currently 
available Zostavax. While these studies are important in the preliminary evaluation of the 
novel vaccine and hold promise for prevention of HZ in older patients, they do not 
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address efficacy or safety concerns in patients who are immunocompromised or 
immunosuppressed, such as IBD patients on immunosuppressive therapy. 
Efficacy, immunogenicity, and safety of HZ/su in immunocompromised patients 
 While there is concern about development of HZ infection from the live-
attenuated vaccine in patients who are immunosuppressed, major considerations with the 
subunit vaccine include the ability of patients to mount a sufficient immune response and 
the safety profile of the vaccine. Unfortunately, no data has been published on HZ/su in 
IBD patients, and there are no ongoing trials in this population according to 
ClinicalTrials.gov;15 however, two studies have investigated its use in other 
immunocompromised populations—HIV-positive individuals and hematopoietic cell 
transplant recipients.  
 Patients living with HIV may have significant defects in CMI, and HZ incidence 
remains higher in these patients despite widespread use of antiretroviral therapy (ART).14 
In a randomized, placebo-controlled, double-blind clinical trial, Berkowitz et al14 
investigated the immunogenicity and safety of HZ/su in HIV-positive patients 18 years of 
age and older. A total of 123 participants were recruited, and three groups were 
established based on CD4 count and whether or not patients were on ART. Patients were 
randomized in a ratio of 3:2 to HZ/zu or placebo. Three doses of vaccine or placebo were 
administered at month 0, 2, and 6; a three-dose regimen was chosen due to uncertainty 
about an adequate response in these patients with a two-dose regimen. Immunogenicity 
was evaluated by assessing CMI parameters (gE-specific CD4+ T cell frequency via ICS) 
and antibody levels (via ELISA) pre-vaccination and at set time points following 
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vaccination. In patients receiving HZ/su, there was a statistically significant increase in 
gE-specific CD4+ T cells compared to placebo when assessed at 7 months (p<0.0001) 
with a peak frequency in gE-specific CD4+ T cells after the second dose without further 
increase after a third dose. After two doses, 85.7% of vaccine recipients had a positive 
response (≥2-fold increase in gE-specific CD4+ T cell frequency from baseline), and 
90% had a positive response after the third dose. In vaccine recipients, 92.3-98.1% met 
the criteria for a positive humoral response at various times during the study, compared to 
less than 2.8% of patients in the placebo group. A significantly higher number of vaccine 
recipients experienced mild to moderate adverse events than those in the placebo group; 
however, there were similar numbers of serious adverse events (two in each group) and 
none were attributed to the vaccine. This study demonstrated that HZ/su was indeed 
immunogenic in HIV-positive patients, although analysis by CD4 count was not 
performed due to the small number of subjects. It is therefore difficult to determine the 
precise effects of different levels of immunosuppression on vaccine response. As with 
previous studies evaluating immunogenicity, CMI and humoral measures cannot be 
correlated to protection against disease, and the threshold for a positive CMI response 
used here (≥2-fold increase from pre-vaccination values) appears to be an arbitrary value. 
However, it is promising that these individuals were able to mount a statistically 
significant immune response and that safety measures were similar to those previously 
seen in immunocompetent participants. 
 An additional study by Stadtmauer et al13 assessed the immunogenicity and safety 
of HZ/su in patients with hematologic malignancies who had received autologous 
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hematopoietic cell transplants. As in IBD patients on immunosuppression and HIV 
patients, these individuals have impaired CMI and are at increased risk of HZ.13 This was 
a phase 1/2a randomized, placebo-controlled, observer-blinded multicenter trial in 121 
individuals who had undergone HCT within the past 50 to 70 days. The trial consisted of 
four arms: two three-dose regimens with different adjuvant concentrations; one two-dose 
gE/AS01B regimen; and a three-dose placebo regimen. Vaccine groups demonstrated 
immune responses superior to placebo in terms of CMI (gE-specific CD4+ T cell 
frequency) and gE antibody levels with multivariate analyses of the combined humoral 
and CMI responses demonstrating a statistically significant superior response in the 
AS01B three-dose regimen compared to the AS01B two-dose regimen, although the 
difference was small. Four cases of HZ were confirmed; two occurred in the gE/AS01B 
three-dose group following cancer progression, and two occurred in the placebo group in 
patients with stable disease. One case of pneumonia was potentially related to 
vaccination, but no other serious adverse events were attributed to study intervention. 
Local and systemic reactions were more common in the vaccine groups than placebo, as 
previously seen. As with previous studies, clinical response cannot be inferred from 
immunologic response here; however, the immune response after vaccination in these 
immunocompromised subjects was similar to that seen in immunocompetent patients in 
previous studies.  
Future directions and ongoing studies 
 Based on these few studies in immunocompromised individuals, the use of HZ/su 
in immunosuppressed IBD patients is promising in terms of its potential to be 
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immunogenic and well-tolerated in this population. Additional studies evaluating vaccine 
efficacy in immunocompromised patients in terms of HZ incidence would be useful, 
although this is difficult given the necessity of a large sample size. With the development 
and investigation of additional immunosuppressive therapeutics to manage the 
manifestations of IBD, an effective and safe means of preventing morbidity and mortality 
related to HZ is ever more important.  
Presently, there are no specific trials underway to evaluate HZ/su in IBD patients, 
although the vaccine itself is now licensed for use in immunocompetent individuals. 
There are currently trials investigating its use in the context of chemotherapy for solid 
organ malignancies, hematologic malignancies, renal transplantation, and 
coadministration with other vaccines.15 These may provide additional evidence 
supporting use of HZ/su in immunosuppressed individuals, but dedicated studies in IBD 
patients, including younger individuals, are needed. 	  
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METHODS 
Study design 
A single-center, prospective clinical trial will be conducted comparing the immune 
response and safety profile of HZ/su in patients with inflammatory bowel diseases treated 
with different levels of immunosuppressive therapy: (1) combination of anti-TNF 
biologics and immunomodulators  or (2) either 5-ASA drugs or no immunosuppression. 
This study design is based on a previous study by Wasan et al27 investigating 
immunogenicity and safety of Zostavax in IBD patients on low-dose immunosuppression 
compared to IBD patients not on systemic immunosuppressive therapy.  
Study population and sampling 
The study population will include patients with IBD who are on a stable regimen of 
combination immunosuppressive therapy or on no systemic immunosuppression as noted 
above and meet the remaining inclusion and exclusion criteria (Table 1). A sample size 
calculation was performed using results from an initial study involving older healthy 
patients (≥60 years of age) who were administered the HZ/su vaccine,43 as there are not 
currently any data available reporting CMI responses to inactivated vaccines in IBD 
patients. It was assumed that IBD patients on 5-ASA or no immunosuppressive therapy 
would have approximately a 20% reduced immune response to the vaccine compared to 
healthy adults. Using these data, the estimated total sample size was 264 participants 
based on calculations assuming an alpha level of 0.05, power of 0.8, and a detectable 
difference in mean increase in gE-specific T cell frequency of 20% between groups. 
Unfortunately, these data are unlikely to truly represent our intended study population 
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and this sample size is not feasible in our center. In light of the limited data and lack of 
established CMI responses to HZ vaccination in IBD patients with which to calculate a 
sample size, and as this is a single-center study, a sample of convenience will be used. 
The study by Wasan et al27 on which this study is modeled, performed at the same 
clinical site, utilized a sample size of 39. Although that study did not lose any patients to 
follow-up, we will assume a 10% drop out rate and attempt to recruit a total of 44 
patients, 22 in each group. This smaller sample size will result in an underpowered study 
(power of 0.18 based on above data) that is unlikely to provide conclusive determinations 
regarding the hypotheses, but it is a goal of this study to demonstrate trends and provide 
preliminary data to inform future studies in this patient population.  
Table 1. Inclusion and exclusion criteria.  
Inclusion Criteria Exclusion Criteria 
1. Patient is 50 years of age or older 
2. Patient has a diagnosis of IBD 
(Crohn’s disease or ulcerative 
colitis based on standard 
diagnostic criteria) 
3. Patient is on current therapy with 
combination of an anti-TNF 
biologic agent (infliximab, 
adalimumab, certolizumab pegol, 
golimumab) AND 
immunomodulator (6-MP, AZA, 
or MTX), OR a 5-ASA agent 
(mesalamine) or no 
immunosuppression 
4. Patient has been on a stable 
treatment regimen for at least 3 
months 
5. Patient has a history of primary 
varicella infection or positive 
VZV serology 
1. Prior herpes zoster vaccination or 
herpes zoster infection 
2. Additional diagnosis of any other 
immune-mediated or 
immunosuppressive disease other 
than IBD (including hematologic 
malignancies, rheumatoid arthritis, 
psoriatic arthritis, ankylosing 
spondylitis, systemic lupus 
erythematosus)  
3. Current pregnancy  
4. Allergy to any vaccine component 
5. Corticosteroid use within 30 days 
of study initiation 
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Treatment 
Two treatment groups will be recruited from the population of eligible patients: (A) 
patients on combination therapy with an anti-TNF agent and immunomodulator, and (B) 
patients treated with a 5-ASA agent or no immunosuppressive therapy. Both groups will 
receive two doses (50 µg gE/AS01B each dose) of the inactivated herpes zoster subunit 
vaccine (HZ/su) two months apart administered by intramuscular injection performed by 
study personnel; this dosing regimen is based upon the current vaccine administration 
recommendations.47  
Study variables and measures 
The primary outcome will be immunogenicity in terms of cell-mediated immune 
response evaluated at four time points (1, 3, 6, 12 months) following completion of the 
second vaccine dose. CMI will be assessed using an intracellular cytokine staining (ICS) 
assay with flow cytometry to determine the frequency of T lymphocytes specifically 
responsive to VZV glycoprotein E (gE), which is the antigenic component of the HZ/su 
vaccine. Immunofluorescent antibody stains against four different cytokines (IFN-γ, 
TNF-α, IL-2, CD20 ligand) are applied to a peripheral blood mononuclear cell sample 
that has been incubated with the gE antigen, and samples are analyzed using flow 
cytometry to determine the frequency of cells expressing each cytokine type.44,48 A cell 
demonstrating expression of at least two different cytokine types in response to antigenic 
stimulation is considered a positively responding cell.43,44 The frequency of positively 
	33 
responding gE-specific T cells is reported. Specifics regarding the assay are described 
elsewhere.43,44,48  
 The secondary outcome will be safety and tolerability of the vaccine. Specific 
local and systemic reactions occurring within 7 days of each vaccine dose will be 
reported by patients via phone call or written patient logs. Patients will also be asked to 
self-report any additional non-solicited symptoms they experience in the 30-day period 
following receipt of the vaccine using written logs that will be reviewed later by study 
personnel. Severe adverse events will be defined as any medical condition resulting in 
hospitalization or death within 12 months of completing the vaccine series or in 
withdrawal from the study prior to receiving the second vaccine dose.  Investigators will 
evaluate each event to determine if it is likely related to the study intervention. We will 
also make note of any suspected cases of HZ occurring during the 12-month follow-up 
period. During the onboarding process, patients will be educated about signs and 
symptoms of HZ and instructed to notify study personnel if they develop these 
symptoms. Patients will then be asked to present for evaluation to confirm the diagnosis. 
Recruitment 
Patients will be recruited from the Center for Digestive Disorders gastroenterology clinic 
at Boston Medical Center in Boston, MA. All patients meeting inclusion criteria will be 
contacted prior to their scheduled outpatient visits to screen for interest in participating in 
the study. Patients indicating interest will be approached by study personnel during their 
office visit to explain the associated implications, risks, and benefits. Informed consent 
will be obtained from those interested in continuing.  
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Data collection 
Demographic information (age, sex, ethnicity) will be collected from patient charts to 
compare group baseline characteristics. Blood samples for immunogenicity studies will 
be obtained prior to vaccination to establish a baseline pre-vaccination level. Additional 
blood samples will be obtained 1, 3, 6, and 12 months following administration of the 
second dose of vaccine. Safety measures will be obtained via phone calls, patient logs, 
and clinic visits. All patient data will be stored in a secure electronic spreadsheet. 
Data analysis 
Mean gE-specific T cell frequencies for each group will be calculated for each time point. 
As there is not yet a threshold of CMI determined to be protective against VZV 
reactivation, we do not have any cutoff value with which to confirm a protective immune 
response. Instead, we will compare T cell frequency change from baseline between 
groups at each time point using unpaired t-tests (or Mann-Whitney test, depending on the 
distribution of the data) in order to evaluate the effect of different levels of 
immunosuppression on CMI response in IBD patients. For the secondary endpoint of 
safety, adverse effects will be compared between groups using a chi-square test (or 
Fisher’s exact test if non-parametric tests are more appropriate).  
Timeline and resources 
Recruitment of subjects will take place over approximately 6 months. Given the small 
sample size, this will allow for nearly two weeks on average to recruit one patient, which 
is feasible with our clinic volume. The vaccine will be administered in two doses given 
two months apart, followed by data collection (immunogenicity studies and adverse 
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events), which will continue for up to 12 months after the second dose of the vaccine, for 
a total study duration of 14 months after recruitment. This will be followed by data 
analysis over the next 6 months. Study personnel will include the primary investigators, 
statistician, and nursing staff for blood draws. The study will also require laboratory 
resources to process the ICS assay and other basic labs noted above. 
Institutional Review Board 
We intend to submit the study proposal for IRB full board review. This study is 
appropriate for full board review given its use of an inactivated vaccine in human 
subjects. Based on initial studies, we do expect an increased rate of mild to moderate side 
effects compared to the live vaccine, which is thought to be related to the adjuvant system 
used. However, we feel that the risks are outweighed by the anticipated direct benefits to 
the study participants in the form of reduced HZ risk. This study’s sample does not 
represent a vulnerable or protected population, and therefore no specific protections are 
needed.  
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CONCLUSION 
Discussion 
The proposed clinical trial will help describe the immunogenicity and safety profile of the 
novel HZ/su vaccine in some of the most significantly immunosuppressed IBD patients 
compared to those who are not treated with systemic immunosuppression. This will allow 
evaluation of IBD patients on opposite ends of the spectrum of immunosuppression 
within the resource limitations of a single-center study.  
 The study design does have several limitations. First, the use of combination 
therapy as its own group precludes a differentiated analysis of anti-TNF agents and 
immunomodulators on their own. However, if these patients are found to be able to 
mount significant immune responses and tolerate the vaccine well, it is likely that patients 
on monotherapy with either of these agents would be able to do the same. Additionally, 
this study design does not compare IBD patients to healthy controls or utilize placebo. 
Initial studies, though, have shown the vaccine to be immunogenic in 
immunocompromised patients, and the goal of this study is to illustrate the effect of 
immunosuppression on vaccine response in IBD patients. Additionally, the primary study 
outcome measures immunogenicity, which does not necessarily translate to efficacy. 
However, efficacy studies would require much larger sample sizes than are feasible in 
this context. Finally, as there are no established CMI metrics in IBD patients receiving 
the HZ vaccine, we were unable to determine a reliable, feasible sample size for an 
adequately powered study and instead propose utilizing a small sample of convenience in 
a single-center study. Most studies investigating vaccine immunogenicity have focused 
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on antibody responses. However, as CMI likely plays the more significant role in 
preventing VZV reactivation, we decided to utilize CMI measures for the primary 
outcome. This presented limitations with respect to statistical planning based on the 
limited availability of prior CMI findings. While this will likely limit the generalizability 
of study findings, one goal of this study is to provide measurements that could be used in 
planning future studies of immunogenicity in IBD patients.  
 There are many future directions for research with respect to herpes zoster 
vaccination and IBD. Future studies are still needed to evaluate the specific effects of 
newer classes of IBD therapeutics on vaccine responses. In particular, the new anti-
integrin agent vedolizumab is believed to act in a gut-specific manner and may not cause 
systemic immunosuppression, while the JAK kinase inhibitor tofacitinib, an emerging 
agent for IBD treatment, may lead to an increased risk of HZ compared to other agents. 
Available vaccines are only approved for ages 50 and older, while IBD patients are often 
diagnosed at earlier ages,17 potentially warranting earlier vaccination. Thus, studies 
evaluating the new vaccine in younger populations should be considered. In this context, 
long-term persistence studies and investigations for the potential of a HZ/su booster 
would be useful for ensuring long-term protection were HZ/su to be used starting at 
earlier ages. 
 At present, there are no CMI thresholds that are known to be protective against HZ 
infection. Establishing protective CMI levels in future studies would help to provide 
means of correlating immunogenicity with protective efficacy and would potentially 
	38 
allow for laboratory tests to confirm protective levels in immunized patients, just as 
antibody levels are utilized for this purpose with other vaccines. 
Summary 
Based on multiple studies, it is evident that patients with inflammatory bowel diseases are 
at increased risk of herpes zoster infection compared to the general population. Much of 
this risk is due to the immunosuppressive therapy needed to control the disease process. 
Different immunosuppressive agents have been associated with different risks of 
developing HZ. There is particular concern about the increased risk of HZ associated 
with the anti-TNF biologics, although data regarding the degree of risk is conflicting.  
 Zostavax is a live-attenuated vaccine that has been available for prevention of HZ 
and its complications for over 10 years; however, many IBD patients are unable to 
receive the vaccine due to their immunosuppressed state. A new inactivated vaccine, 
Shingrix, was recently licensed for use in immunocompetent patients and has been 
demonstrated to be highly immunogenic and tolerable in the immunocompromised 
patients in whom it has been studied. 
 The new vaccine does not yet have recommendations for use in 
immunocompromised patients and has not been studied in IBD patients yet. Thus, there is 
a gap in the current knowledge regarding the immunogenicity and safety profile of the 
vaccine in this subset of patients. Additionally, there is no established threshold of CMI 
measurements for protection against the disease, which limits the utility of 
immunogenicity studies. The proposed study seeks to improve the knowledge of the new 
vaccine’s safety and immunologic profile in IBD patients treated with different degrees 
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of immunosuppressive therapy. The findings of this study, including estimates of CMI 
responses to the inactivated vaccine, will help to inform future research on HZ prevention 
in this population. 
Clinical and/or public health significance 
Patients with IBD are at up to twice the risk of HZ infection given their disease state and 
immunosuppressive therapies compared to the general population. At present, there are 
very limited options for preventing HZ in IBD patients. With the licensure of an 
inactivated vaccine for HZ, there is potential for vaccination of IBD patients on active 
immunosuppression. Establishment of safety and immunogenicity of the vaccine in this 
group may eliminate some of the hesitation to vaccinate these patients that has been 
associated with the live vaccine. With the new inactivated vaccine demonstrating efficacy 
rates over 90% in immunocompetent patients, compared to about 50% with Zostavax, 
there is even further potential for the new vaccine to mitigate the incidence and 
complications of this potentially debilitating illness in IBD patients. 
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